Results 171 to 180 of about 129,145 (314)

Exclusive patent, know-how, process, technology and trade secret license to develop, make, have made, use, sell, have sold, import, export, improve and sublicense pharmaceutical products containing lasofoxifene tartrate alone or in combination with other active ingredients, for oral use in the treatment or prevention of human diseases, including metastatic breast cancer.

RoyaltyStat
openalex   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

<i>Coffea arabica</i>: An Emerging Active Ingredient in Dermato-Cosmetic Applications. [PDF]

Pharmaceuticals (Basel)
Ruse G, Jîjie AR, Moacă EA, Pătrașcu D, Ardelean F, Jojic AA, Ardelean S, Tchiakpe-Antal DS.   +7 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Exclusive patent, know-how, technology and trade secret license to use the 'Hemangeol' trademarks and trade names to offer, sell, import, exploit, commercialize, dispose of, make, have made and sublicense an oral pharmaceutical solution product containing propranolol as active pharmaceutical ingredient, including improvements, line extensions and modifications, to treat infantile hemangioma.

RoyaltyStat
openalex   +1 more source

Adenosine as an Active Ingredient in Topical Preparations Against Hair Loss: A Systematic Review and Meta-Analysis of Published Clinical Trials. [PDF]

Biomolecules
Szendzielorz E, Spiewak R.
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Exclusive copyright, patent, know-how, process, technology, software, trademark and trade secret license to research, develop, make, have made, use, sell, have sold, offer, import, export, register, commercialize, exploit and sublicense final form pharmaceutical compositions and preparations containing a Jak inhibitor compound, derivative or formulation, alone or in combination with other active ingredients, to treat immuno-inflammatory and other conditions, and any other fields of use.

RoyaltyStat
openalex   +1 more source

Analysis of the Stability of Compounded Vancomycin Hydrochloride Oral Solution: A Comparison Between Formulations Prepared Using a Commercial Product and Using the Pure Active Ingredient. [PDF]

Cureus
Arroyo-Solorzano JD, Martínez-Carpio S, Blanco-Barrantes J, Pacheco-Molina J, Loría-Gutiérrez A, Arguedas-Chacón S, Zavaleta-Monestel E.   +6 more
europepmc   +1 more source